SCHEMBL6646145

SCHEMBL6646145

Cc1ccc(C2=C(C(=O)Nc3ccc4c(c3)CN(C(=O)Cn3cccn3)C4)CCCC2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 5/20 0.41
TMPRSS2 O15393 1/20 0.40
NPC1 O15118 5/20 0.39
RAB9A P51151 5/20 0.39
GAA P10253 1/20 0.39
GFER P55789 1/20 0.39
ALDH1A1 P00352 2/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
KMT2A Q03164 2/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
MAPK1 P28482 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
HIF1A Q16665 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6644758 0.91 RAB9A (0.40) NAMPTNPC1RAB9AGAAGFER
SCHEMBL6644649 0.89 NAMPT (0.42) NAMPTNPC1RAB9AGFERALDH1A1
SCHEMBL6646419 0.85 MAPT (0.47) NAMPTNPC1RAB9AALDH1A1MAPT
SCHEMBL6643248 0.84 ALDH1A1 (0.46) ALDH1A1MAPTKMT2AUSP2LMNA
SCHEMBL6648345 0.78 THRB (0.41) NAMPTNPC1RAB9AALDH1A1MAPT
SCHEMBL6649355 0.78 NAMPT (0.41) NAMPTTMPRSS2NPC1RAB9AGAA
SCHEMBL6923425 0.77 ADORA3 (0.39) MAPTKMT2ALMNAHPGDTSHR
SCHEMBL6646086 0.76 THRB (0.51) NPC1RAB9AALDH1A1MAPTSMN1; SMN2
SCHEMBL6649867 0.76 HTR2C (0.42) NPC1RAB9AGAAALDH1A1MAPT
SCHEMBL6647399 0.75 THRB (0.39) NAMPTNPC1RAB9AGFERALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040133008-A1 Amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-07-08 US disclosed
WO-2004039795-A2 AMIDE COMPOUNDS FOR THE TREATMENT OF HYPERLIPIDEMIA FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040133008-A1 Amide compounds APOB, APOL1, LDLR NAMPT 2225/4885TMPRSS2 2763/4885NPC1 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.